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Abstract 
Background: To evaluate the effect of tumor burden (TB) on survival in patients 
with metastatic renal cell carcinoma (mRCC) who are administered sequential 
molecular-targeted therapy (TT). 
Methods: Sixty-eight patients were recruited. Baseline TB at the time of second-
line TT initiation was calculated according to the Response Evaluation Criteria in 
Solid Tumors v. 1.1. Patients were divided into 2 subgroups according to the 
median TB: greater than the median as the high group, lower than the median as 
the low group. Progression-free survival (PFS) and overall survival (OS) after 
second-line therapy were analyzed. The effect of TB changes on survival during 
sequential TT were also evaluated.  
Results: Median second-line TB was 57.7 cm. The patients with high TB had 
significantly poorer PFS and OS, compared to those with low TB (median PFS, 
4.36 vs. 8.19 months, p = 0.0119; OS, 9.6 vs. 23.5 months, p = 0.0107). For PFS, 
multivariate analyses revealed that second-line objective response was an 
independent predictor (p < 0.0001), but second-line TB was not (p = 0.0826). For 
OS, second -line TB and objective response were independent predictors (p = 
0.0300 and < 0.0001, respectively). Moreover, there was a positive correlation 
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between first- and second-line TB (r2 = 0.460, p < 0.0001), although TB changes 
between first- and second-line therapies did not affect survival (median PFS, p = 
0.812; OS, p = 0.415). 
Conclusions: Second-line TB was an independent predictor of OS among 
patients with mRCC after second-line TT. 
 
Mini-abstract  
Second-line tumor burden was an independent predictor of overall survival 
among patients with metastatic renal cell carcinoma after second-line molecular-
targeted therapy. 
 
Key words 
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Introduction 
 Molecular-targeted agents for the treatment of metastatic renal cell carcinoma 
(mRCC) have been developed. Compared with cytokine therapy, these new 
drugs have significantly improved prognosis in patients with mRCC (1, 2). 
Because of improvements in response, numerus investigations into potential 
predictors or biomarkers of survival have been conducted, and prognostic models 
have been described to help to stratify the risks of disease progression or death 
(3). In this context, imaging findings, according to the standard Response 
Evaluation Criteria in Solid Tumors (RECIST) (4), have been identified as 
objective and effective prognostic indictors. Lacovelli et al. (5) suggested that 
tumor burden (TB), which was defined as the sum of the longest unidimensional 
diameter of each target lesion (restricted to axial CT), at the time of first-line 
molecular-targeted therapy (TT) initiation was an independent prognosticator of 
survival in patients with mRCC. However, for sequential TT, the effect of TB on 
prognosis in patients with mRCC is unknown. Moreover, Lacovelli et al. (5) 
included patients who had received prior cytokine therapy (6, 7). Therefore, to the 
best of our knowledge, there are limited studies that have investigated the effect 
of TB on survival during sequential TT in patients who have not undergone prior 
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cytokine therapy.  
Thus, the aim of this study was to evaluate the predictive role of second-line TB 
on survival among mRCC patients who underwent second-line TT without prior 
cytokine therapy. Moreover, the influence of TB changes during sequential TT on 
survival was investigated. 
 
Patients and methods 
Patients and study design 
The Internal Ethics Review Board of Tokyo Women’s Medical University 
approved this retrospective study (ID: 3942), which was performed in accordance 
with the principals outlined in the Declaration of Helsinki.  
 In our department, 120 patients underwent second-line targeted therapy (37 
were administered sunitinib; 3, sorafenib; 4, pazopanib; 43, axitinib; 11, 
temsirolimus; and 22, everolimus) between January 2008 and March 2016. 
Among these, 29 patients who underwent prior cytokine therapy, 7 patients who 
underwent dialysis therapy, and 11 patients who experienced adverse events 
during first-line therapy were excluded. For the remaining 76 patients, 8 patients 
whose clinical (n = 4) or imaging (n = 4) data were not available were also 
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excluded. Finally, 68 patients (19 were administered sunitinib; 2, sorafenib; 3, 
pazopanib; 32, axitinib; 4, temsirolimus; and 8, everolimus) were enrolled in this 
retrospective study (Figure 1). Clinical and laboratory data were obtained from 
the electronic database and patient medical records. 
 
Imaging methods and imaging evaluation 
Baseline imaging examinations, including plain or contrast-enhanced CT or MRI 
of the chest, abdomen, and pelvis were performed within 28 days before the start 
of a new therapy. The target lesions were selected based on the baseline imaging 
results, and were evaluated according to RECIST v. 1.1 (4) i.e., a maximum of 5 
lesions, with a maximum of 2 per organ per patient. Lymph nodes were only 
selected as target lesions if the short axis was longer than 15mm. Sclerotic 
osseous lesions were excluded. Two investigators (HI and TK), who were blinded 
to all other clinical parameters and outcomes, performed the image analyses.  
 
Statistical analysis  
Continuous variables were analyzed using the Mann-Whitney U-test, and 
categorical variables were analyzed using the χ2 test. To evaluate the influence 
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of second-line TB on patient outcomes, patients were divided into 2 subgroups 
according to the TB value as higher than the median (high group) or lower than 
the median (low group). Progression-free survival (PFS) and overall survival (OS) 
after second-line therapy were compared between the groups using the Kaplan-
Meier method and the log-rank test. PFS was defined as the time of second-line 
therapy initiation to the date of progression or death from any cause. OS was 
defined as the time of second-line therapy initiation to death from any cause. 
Univariate and multivariate analyses using Cox proportional hazards regression 
models were used to identify factors that were associated with PFS and OS. First- 
and second-line TB were calculated for each patient and first-line TB was plotted 
against second-line TB on a scatter plot. Pearson’s correlation coefficient was 
used to compare first- and second-line TB. To evaluate the influence of TB 
changes on survival, the correlation between first- and second-line TB at the time 
of treatment initiation was evaluated by dividing patients into three subgroups 
according to the ratio of second-line to first-line TB (i.e., [second-line TB – first-
line TB]/first-line TB): Group A: ≥ 0.2, Group B: ≤ -0.2, and Group C: between -
0.2 and 0.2. PFS and OS were compared among the three groups. Survival risk 
was expressed as hazard ratios (HR) and 95% confidence intervals (CIs). All 
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analyses were performed using JMP software (version 11; SAS Institute Inc., Cary, 
NC, USA), and a p-values of <0.05 was considered statistically significant. 
 
Results 
Patients’ characteristics  
 The patients’ characteristics are shown in Table 1. The mean age was 64.3 years 
(median, 67.5 years; range 29–87 years). Second-line Memorial Sloan Kettering 
Cancer Center (MSKCC) risk classification was identified according to Motzer’s 
risk classification (8). 
  
Survival according to second-line tumor burden 
 Figure 2 shows the Kaplan-Meier survival curves of PFS and OS after second-
line therapy according to second-line TB. The patients with high TB had 
significantly lower PFS and OS, compared to the patients with low TB (median 
PFS, 4.36 vs. 8.19 months, p = 0.0119; OS, 9.6 vs. 23.5 months, p = 0.0107).  
 
Survival according to first-line tumor burden 
 Figure 3 shows the Kaplan-Meier survival curves of first-line PFS and OS after 
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first-line therapy according to first-line TB. Similar to second-line, patients were 
divided into two subgroups according to TB value: higher than the median (high 
group) or lower than the median (low group). The OS rate was significantly lower 
in patients with high TB compared to those with low TB (median, 20.6 vs. 43.8 
months, p = 0.0091), whereas PFS did not significantly differ between the two 
groups (median, 7.91 vs 8.43 months, p = 0.193).  
 
Predictors of survival 
 On univariate analysis, significant predictors of PFS were second-line MSKCC, 
pathology, second-line TB, and objective response (OR) (all, p < 0.05). On 
multivariate analysis, for PFS, second-line OR was an independent predictor (p 
< 0.0001) (Table 2). On univariate analysis, significant predictors of OS were 
second-line MSKCC, pathology, first-line agent, second-line TB, and OR (all, p < 
0.05). On multivariate analysis, for OS, second-line TB and OR were independent 
predictors (HR 1.01, p = 0.0207; and p < 0.0001, respectively) (Table 3). 
 
Impact of tumor burden changes on survival during sequential molecular-targeted 
therapy  
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Figure 4 shows that there was a positive correlation between first- and second-
line TB (r2 = 0.460, p < 0.0001), Moreover, according to subgroup classification 
based on the TB changes from first- to second-line therapy, 29 (42.6%), 19 
(27.9%), and 20 (29.4%) patients were categorized in Groups A, B, and C, 
respectively. Figure 5 shows that there were no significant differences in PFS and 
OS between the groups (median PFS, 7.2, 6.84, and 5.96 months, p = 0.812; OS, 
13.2, 11.1, and 23.5 months, p = 0.415 in Groups A, B, and C, respectively). 
  
Discussion 
The present study revealed that second-line TB was an independent predictor 
of OS but not PFS after second-line TT among patients with mRCC who did not 
undergo prior cytokine therapy. There was also a significant correlation between 
first- and second-line TB, although TB changes during sequential TT did not 
significantly affect PFS or OS. To the best of our knowledge, this is the first study 
to evaluate TB during sequential TT in patients with mRCC who did not undergo 
prior cytokine therapy. 
 TB has been suggested as a useful prognosticator in many malignancies. With 
regard to renal cancers, its role in predicting survival has been previously 
12 
 
identified (5). Using clinical data from previous prospective trials, Lacovelli et al. 
(5) first identified the influence of TB on mRCC patient survival at the time of first-
line TT initiation (5). According to that study, after the patients were divided into 3 
subgroups based on TB values, there were significant differences in the first, 
second, and third tertile of PFS and OS, and TB (per 1cm-increase) was a 
prognostic factor for PFS and OS. However, some patients in their cohort had 
undergone prior cytokine therapy. In clinical practice, TT is a current treatment 
strategy for mRCC (9, 10), but data from patients who had not undergone prior 
cytokine therapy is lacking. Moreover, OR to second-line TT was not evaluated 
in the previous study (5). OR is a useful prognosticator in mRCC patients during 
TT (11-13), and in the present analysis second-line TB and OR were independent 
prognosticators of OS. We believe that these results are important for predicting 
prognosis in mRCC patients undergoing TT because OR is a strong predictor of 
outcome. However, second-line OR cannot be evaluated prior to treatment, 
whereas second-line TB can be easily evaluated prior to second-line TT initiation. 
Therefore, the present study shows that both second-line TB and OR, according 
to imaging findings, can effectively predict patient prognosis and improve 
treatment strategies for mRCC.    
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 We also found that first-line TB was associated with OS, suggesting that TB was 
a useful predictive factor for OS with both first- and second-line therapy. 
Meanwhile, first-line PFS was not associated with TB. In addition, as reported by 
Lacovelli et al. (5), the Kaplan-Meier PFS curve between the first- and second-
tertiles showed no difference, although the multivariate analysis showed a 
significant influence of TB on PFS. Thus, the impact of TB as a predictor for PFS 
may remain controversial.  
 Previous studies have suggested that TB was a significant predictive marker of 
malignant potential not only for metastatic lesions but also for primary renal 
lesions. In a cohort of 2770 patients who underwent surgery for localized renal 
tumors, Frank et al. (14) demonstrated that as tumor size increased there was a 
significant increase in the proportion of clear-cell carcinoma and high grade 
malignancy in renal tumors. Similarly, Thomson et al. (15) demonstrated that 
each 1cm-increase in renal tumor size was associated with a 16% increase in the 
risk for malignancy, and for patients with clear-cell carcinoma, each 1cm-increase 
in tumor size increased the risk of a high-grade tumor. They also suggested that 
primary tumor size was significantly associated with the risk of synchronous 
metastasis and inferior metastases-free survival in patients with non-metastatic 
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RCC (16).  
The present study found that there was significantly relativity between first- and 
second-line TB. This is congruent with the findings of a previous study. In patients 
with mRCC undergoing tyrosine kinase inhibitor treatment, Yuasa et al. (17) found 
that the magnitude of tumor shrinkage depended on the initial TB. According to 
their study, a higher initial tumor volume and poorer tumor shrinkage resulted in 
a higher tumor volume at the time of second-line therapy initiation. However, TB 
changes between first- and second-line therapies did not influence patient 
outcome. In other words, the magnitude of tumor shrinkage during first-line 
therapy did not affect second-line survival, suggesting a lack of correlation 
between first-line PFS and second-line survival (11, 18). Our previous study in 
mRCC patients undergoing sequential TT indicated that neither the magnitude of 
tumor shrinkage during first-line therapy nor first-line PFS were associated with 
second-line PFS or OS (12). Moreover, several previous studies suggested that 
there was no correlation between first- and second-line vascular endothelial 
growth factor inhibitor (VEGFi) treatment, and that the clinical response to a 
second-line VEGFi was not dependent on response to the first-line VEGFi (19, 
20). Therefore, the results of the present study are consistent with those of 
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previous studies.  
Finally, this study may support the indication of a new drug (programmed death-
1 (PD-1) checkpoint inhibitor: nivolumab) as a second-line agent. A previous 
pivotal randomized trial demonstrated the efficacy of this drug in cohorts of 
patients with mRCC who had received one or two previous regimens of 
antiangiogenic therapy (21). As patients with high TB have poor prognoses, even 
after initiation of second-line TT consisting of conventional agents, we may need 
to treat such high-risk patients with nivolumab. However, the association between 
TB and nivolumab remains unclear, and this suggestion should be confirmed in 
future investigations. 
The present study had several limitations. First, this study was performed 
retrospectively in a single-center with small cohort; therefore, there may be 
unavoidable patient selection bias. Second, during the follow-up period, the 
strategy of sequential TT was inconsistent. Recently sequential TT in our institute 
consisted of first-line sunitinib and second-line axitinib, however, in previous era, 
because of lack of TT approval, different regimens were used. For example, 
before sunitinib was approved (prior to 2008), sorafenib was administered as a 
first-line agent, and before axitinib was approved (prior to 2012), temsirolimus or 
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everolimus was administered as a second-line agent. Moreover, in several cases 
of non-clear cell carcinoma, or high risk based on MSKCC classification, 
temsirolimus rather than tyrosine kinase inhibitors was used as a first-line agent 
(10). However, multivariate analysis including factors such as pathology, MSKCC 
classification, and targeted agents was performed to remove selection bias as 
much possible. Therefore, the findings of the present study should be confirmed 
in a prospective study with a large and homogenous patient cohort.  
 In conclusion, the present study revealed that second-line TB was an 
independent predictor of second-line OS among patients who underwent 
sequential TT without prior cytokine therapy. Moreover, we found that there was 
significant correlation between first- and second-line TB, whereas TB changes 
between first- and second-line therapies did not affect PFS or OS. Our results, 
based on imaging examination prior to second-line therapy initiation, might 
enable more effective prognosis prediction and improve mRCC treatment 
strategies. Moreover, when shifting to second-line therapy, it might not be 
necessary to consider the clinical response during first-line therapy.  
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Figure legends 
Figure 1: Patient selection 
SU, sunitinib; SO, sorafenib; PA, pazopanib; AX, axitinib; TE, temsirolimus; EV, 
everolimus 
 
Figure 2: Patient survival according to second-line tumor burden 
The patients were classified into two groups according to second-line TB; 34 
patients were classified into the high TB group (≥ 57.7 cm), and the remaining 34 
patients were classified into the low TB group (< 57.7 cm). The PFS and OS rates 
were calculated using the Kaplan-Meier method and were compared using the 
log-rank test (PFS, p = 0.0119; OS, p = 0.0107). 
TB, tumor burden; PFS, progression-free survival; OS, overall survival 
 
Figure 3: Patient survival according to first-line tumor burden 
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The patients were classified into two groups according to first-line TB; 34 patients 
were classified into the high TB group (≥ 47.0 cm), and the remaining 34 patients 
were classified into the low TB group (< 47.0 cm). The PFS and OS rates were 
calculated using the Kaplan-Meier method and were compared using the log-rank 
test (PFS, p = 0.193; OS, p = 0.0091).  
TB, tumor burden; PFS, progression-free survival; OS, overall survival 
 
Figure 4: Correlation of tumor burden between first- and second-line therapies 
Pearson’s correlation coefficient analysis showed that there was a positive 
correlation between first- and second-line TB (r2 = 0.460, p < 0.0001).  
TB, tumor burden 
 
Figure 5: Patient survival according to tumor burden changes between first- and 
second-line therapies 
The PFS and OS rates were calculated using the Kaplan-Meier method and 
compared using the log-rank test (PFS, p = 0.812; OS, p = 0.415). TB changes 
were calculated as follows: (second-line TB – first-line TB)/first-line TB.  
PFS, progression-free survival; OS, overall survival, TB; tumor burden 
Table 1: Patient background 
Variable Number (n = 68) 
Age at second-line therapy initiation (years) 
 ≥ 65 
 < 65 
 
41 (60.3%) 
27 (39.7%) 
Sex 
 Male 
 Female 
 
45 (66.2%) 
23 (33.8%) 
First-line MSKCC 
 Favorable 
 Intermediate 
 Poor 
 
10 (14.7%) 
48 (70.6%) 
10 (14.7%) 
Second-line MSKCC 
 Favorable 
 Intermediate  
 Poor 
 
6 (8.82%) 
41 (60.3%) 
21 (30.9%) 
Prior nephrectomy 
 Yes  
 
64 (94.1%) 
 No 4 (5.88%) 
Pathology 
 Clear cell carcinoma 
 Non-clear cell carcinoma 
  Clear cell carcinoma with spindle 
  Papillary renal cell carcinoma type 2 
  Mucinous tubular and spindle cell carcinoma 
  Medullary carcinoma 
  Unknown 
 
48 (70.6%) 
20 (29.4%) 
4 (5.88%) 
11 (16.2%) 
1 (1.47%) 
1 (1.47%) 
3 (4.41%) 
First-line agent 
 TKI 
  Sunitinib 
  Sorafenib 
  Pazopanib 
 mTORi 
  Temsirolimus 
  Everolimus 
 
60 (88.2%) 
36 (52.9%) 
21 (30.9%) 
3 (4.41%) 
8 (11.8%) 
7 (10.3%) 
1 (1.47%) 
Second-line agent 
 TKI 
  Sunitinib 
  Sorafenib 
  Pazopanib 
  Axitinib 
 mTORi 
  Temsirolimus 
  Everolimus 
 
56 (82.3%) 
19 (27.9%) 
2 (2.94%) 
3 (4.41%) 
32 (47.1%) 
12 (17.6%) 
4 (5.88%) 
8 (11.8%) 
Metastatic organs 
 Lung 
 Liver 
 Bone 
 Lymph nodes 
 Others 
 
29 (42.6%) 
10 (14.7%) 
7 (10.3%) 
18 (26.5%) 
12 (17.6%) 
First-line tumor burden (cm) 69.2 (47.0, 10 – 427) 
Second-line objective response 
 Complete response 
 
1 (1.47%) 
 Partial response 
 Stable disease 
 Progression disease  
11 (16.2%) 
41 (60.3%) 
15 (22.1%) 
Second-line tumor burden (cm) 82.6 (57.7, 10.6 – 313) 
Disease progression 
 Yes  
 No 
 
54 (79.4%) 
14 (20.6%) 
Death from any cause 
 Yes   
 No 
 
43 (63.2%) 
25 (36.8%) 
Follow-up period (months) 14.2 (10.5, 1.81 – 50.7) 
MSKCC, Memorial Sloan Kettering Cancer Center; TKI, tyrosine kinase 
inhibitor; mTORi, mammalian target of rapamycin inhibitor   
 
 
 
 
 
Table 2: Univariate and multivariate analyses for second-line PFS 
Variable Univariate 
HR (95%CI) 
p Multivariate  
HR (95%CI) 
p 
Age  
 ≥ 65 
 < 65 
 
Reference 
1.30 (0.74 – 2.23) 
0.354 
  
Sex 
 Male 
 Female 
 
Reference 
1.27 (0.72 – 2.21) 
0.400 
  
First-line MSKCC 
 Favorable/intermediate 
 Poor 
 
Reference 
1.11 (0.45 – 2.33) 
0.803 
  
Second-line MSKCC 
 Favorable/intermediate 
 Poor 
 
Reference 
2.69 (1.45 – 4.87) 
0.0021  
Reference 
1.72 (0.90 – 3.25) 
0.100 
Pathology 
 CCC 
 Non-CCC 
 
Reference 
2.98 (1.63 – 5.30) 
0.0006  
Reference 
1.72 (0.88 – 3.30) 
0.112 
First-line agent 
 TKI 
 mTORi 
 
Reference 
1.67 (0.73 – 3.37) 
0.212 
  
Second-line agent 
 TKI 
 mTORi 
 
Reference 
1.53 (0.77 – 2.85) 
0.216 
  
Second-line objective response 
 Complete and partial response 
 Stable disease 
 Progression disease    
 
0.30 (0.11 – 0.68) 
Reference 
27.8 (9.76 – 92.7) 
<0.0001 
0.0031 
- 
<0.0001 
 
0.39 (0.14 – 0.94) 
Reference 
25.9 (8.78 – 89.3) 
<0.0001 
0.0364 
- 
<0.0001 
Second-line tumor burden 1.01 (1.00 – 1.01) 0.0006 1.00 (1.00 – 1.01) 0.0826 
PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; 
MSKCC, Memorial Sloan Kettering Cancer Center; TKI, tyrosine kinase 
inhibitor; mTORi, mammalian target of rapamycin inhibitor   
 
 
 
 
Table 3: Univariate and multivariate analyses for second-line OS 
Variable Univariate 
HR (95%CI) 
p Multivariate  
HR (95%CI) 
p 
Age 
 ≥ 65 
 < 65 
 
Reference 
1.52 (0.82 – 2.80) 
0.179 
  
Sex 
 Male 
 Female 
 
Reference 
1.35 (0.72 – 2.49) 
0.345 
  
First-line MSKCC 
 Favorable/intermediate 
 Poor 
 
Reference 
1.70 (0.63 – 3.88) 
0.267 
  
Second-line MSKCC 
 Favorable/intermediate 
 Poor 
 
Reference 
3.37 (1.76 – 6.32) 
0.0004  
Reference 
1.89 (0.86 – 3.98) 
0.109 
Pathology 
 CCC 
 Non-CCC 
 
Reference 
3.06 (1.58 – 5.75) 
0.0013  
Reference 
1.16 (0.51 – 2.54) 
0.725 
First-line agent 
 TKI 
 mTORi 
 
Reference 
3.34 (1.40 – 7.14) 
0.0085  
Reference 
2.33 (0.86 – 5.97) 
0.0940 
Second-line agent 
 TKI 
 mTORi 
 
1.24 (0.61 – 2.76) 
Reference 
0.557 
  
Second-line objective response 
 Complete and partial response 
 Stable disease 
 Progression disease    
 
0.28 (0.08 – 0.72) 
Reference 
8.48 (3.56 – 19.9) 
<0.0001 
0.0066 
- 
<0.0001 
 
0.38 (0.10 – 1.09) 
Reference 
7.93 (3.07 – 20.6) 
<0.0001 
0.0743 
- 
<0.0001 
Second-line tumor burden 1.01 (1.00 – 1.01) 0.0002 1.01 (1.00 – 1.01) 0.0300 
OS, overall survival; HR, hazard ratio; CI, confidence interval; MSKCC, 
Memorial Sloan Kettering Cancer Center; TKI, tyrosine kinase inhibitor; mTORi, 
mammalian target of rapamycin inhibitor   
 





